Related Experiment Video

Updated: Mar 30, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.2K

Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease

Murugan Kalimutho1, Kate Parsons2, Deepak Mittal3

  • 1Signal Transduction Laboratory, Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute, Herston, Brisbane, QLD 4006, Australia.

Trends in Pharmacological Sciences
|November 6, 2015
PubMed

Insights

Triple-negative breast cancer (TNBC) treatments face challenges from tumor heterogeneity and resistance. This review explores emerging targeted therapies, including immunotherapy, and combination strategies to improve outcomes for TNBC patients.

Area of Science:

  • Oncology
  • Cancer Therapeutics
  • Molecular Biology

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis and limited targeted therapies.
  • Despite molecular profiling identifying potential targets, clinical trial results for TNBC remain modest.
  • Tumor heterogeneity and acquired resistance pose significant challenges to effective treatment.

Purpose of the Study:

  • To comprehensively review emerging targeted therapies for TNBC.
  • To discuss the role of immunotherapy and tumor-infiltrating lymphocytes in TNBC treatment.
  • To explore strategies for overcoming drug resistance and improving clinical outcomes.

Main Methods:

  • Literature review of recent studies on TNBC targeted therapies.
  • Analysis of molecular-profiling data and clinical trial outcomes.
  • Discussion of resistance mechanisms and combination therapy approaches.

Main Results:

  • Several promising molecular targets and candidate compounds are in clinical development for TNBC.
  • Immunotherapy, including the prognostic value of tumor-infiltrating lymphocytes, shows potential.
  • Pathway rewiring significantly contributes to acquired drug resistance.

Conclusions:

  • Combination therapy strategies are crucial for overcoming resistance and improving TNBC treatment efficacy.
  • Further research is needed to identify clinically viable targeted treatment options for TNBC.
  • Addressing tumor heterogeneity is key to successful TNBC therapeutic development.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K